Jeroen Bosch Hospital
- Address
- Henri Dunantstraat 1, 5223 GV S-Hertogenbosch, The Netherlands
Cardiovascular Diseases
At Jeroen Bosch Hospital, the Pulmonary Science department is conducting research that addresses heart rhythm disturbances linked to acute stress, focusing on preventing serious vascular events.
- Evaluation of anticoagulants versus no anticoagulation for transient atrial fibrillation
- Assessment of composite outcomes including stroke, systemic embolism, and vascular mortality
- Exploration of safety and efficacy in patients undergoing non‑cardiac surgery or acute illness
The trials aim to improve guidelines for anticoagulation management and reduce the risk of stroke in high‑risk patients.
Respiratory Tract Diseases
Research at the same site investigates inflammatory lung disease, testing alternative first‑line treatments to enhance patient outcomes.
- Comparison of methotrexate with prednisone in newly diagnosed pulmonary sarcoidosis
- Measurement of disease activity, lung function, and tolerability
- Focus on reducing corticosteroid exposure while maintaining disease control
The study seeks to identify safer, effective options for managing sarcoidosis and improving quality of life.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 271 other sites in The Netherlands
Therapeutic Area Benchmark — The Netherlands
Select a therapeutic area to compare against other sites in The Netherlands.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: The Netherlands
Market Share
Country: The Netherlands
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Jeroen Bosch Hospital
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Randomized Controlled Trial Comparing Methotrexate and Prednisone as First-Line Therapy in Patients with Pulmonary Sarcoidosis | Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) | Phase III | Recruiting | Nov 2024 | — |
IMP list
lock Showing 1 of 10 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Apixaban | 2 | Unknown | 2024-01-29 | 2024-12-16 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.